Here are five things to know about the company:
1. InVivo’s shares have increased 177 percent this year so far after adding patients to a clinical trial using the Neuro-Spinal Scaffold for spinal cord injury.
2. The shares reached $14.61 this year, and positive news from current and future patients in the trial could spark additional growth.
3. The current clinical trial includes both young and active patients as well as an older patient who could benefit from the spinal cord injury treatment. The older patient went from having complete paralysis to incomplete paralysis after a month.
4. There are not any other players in this particular market for spinal cord injury treatment, making the field open if the implant proves effective.
5. The company’s treatments are gaining attention outside the clinical realm. The first two patients treated are young and active on social media, providing updates on their condition. They are also attracting attention for becoming romantically involved after their injuries.
More articles on orthopedic devices:
Integra LifeSciences shares up by 3.15%: 5 quick facts
Global MIS instruments market to reach $14B+ by 2019: 5 key trends
Japanese medical device company partners with Materialise for hip technology
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
